ATX
AMPLIA FPO [ATX]
Healthcare · ASX Small Cap
$0.1220 +1.7%
Updated 2026-03-02 · Scores refresh every scan
Appeared in 2 consecutive scans→ Score +4First seen: 2026-02-25
Score Breakdown
Technical45
Catalyst50
Sentiment50
Fundamental77
Momentum76
Risk Gate50
Active Signals
Bullish Signals
- Bollinger squeeze (breakout building)
- Above-average volume (1.9x) on up day
- Strong cash runway (9 quarters)
- 4C filed 2026-01-29
- Moderate P/S ratio (12.3x)
- Strong revenue growth (+87%)
- EPS estimates revised downward (-6pts)
- Near 52-week low (19% of range)
- Small-cap ($20-100M)
- CANSLIM I: Institutional ownership (19%)
- Strong 12-1 momentum (+132%)
- Strong revenue momentum (+87%)
- ASX200 bullish (+1.5% 5d)
- RBA cutting (+2pts)
- Trial readout: PHASE1 (est. 2026-05-01)
Risk Signals
- Price below MAs (downtrend)
- Negative 5-day momentum (-6.2%)
- Below 200-day MA (long-term downtrend)
- Deeply negative margins (-158%)
- Insufficient sentiment data (defaulting to neutral)
- Neutral/mixed sentiment
Recent Catalysts
NONE Appointment of Chief Financial Officer
NONE US Sites For AMPLICITY Pancreatic Cancer Trial Open
NONE Change in substantial holding
LOW Amplia Emergence 2026 Conference Presentation
LOW Quarterly Activities/Appendix 4C Cash Flow Report
Recent ASX Announcements
| 2026-02-24 | Appointment of Chief Financial Officer |
| 2026-02-17 | Amplia Emergence 2026 Conference Presentation |
| 2026-02-10 | US Sites For AMPLICITY Pancreatic Cancer Trial Open |
| 2026-01-29 | Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE |
| 2026-01-22 | Change in substantial holding |
Key Metrics
$61.6M
Market Cap
439K
Avg Volume
1.9x
Vol Ratio
$0.05 — $0.42
52-Week Range
0.1%
Short Interest
9 qtrs
Cash Runway
-28.5%
ROE
-158.5%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 85% |
| L | Leader vs Laggard | laggard | RS: -0 |
| I | Institutional Sponsorship | pass | Inst: 19% |
| M | Market Direction | pass | Bullish |
Sector: Healthcare
Ranked #15 of 119 · Sector avg: 51
View all Healthcare signals →